The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of pathological response and recurrence pattern on the survival of patients who develop recurrence from neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC).
 
Chien Huai Chuang
No Relationships to Disclose
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; Bayer; Ipsen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
Consulting or Advisory Role - MSD; Ono Pharmaceutical
 
Ta-Chen Huang
No Relationships to Disclose
 
Tsung-Che Wu
Honoraria - Astellas Pharma; Bayer; Janssen
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)